BE2010C011I2 - - Google Patents
Info
- Publication number
- BE2010C011I2 BE2010C011I2 BE2010C011C BE2010C011C BE2010C011I2 BE 2010C011 I2 BE2010C011 I2 BE 2010C011I2 BE 2010C011 C BE2010C011 C BE 2010C011C BE 2010C011 C BE2010C011 C BE 2010C011C BE 2010C011 I2 BE2010C011 I2 BE 2010C011I2
- Authority
- BE
- Belgium
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/74—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
- C07C215/76—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton of the same non-condensed six-membered aromatic ring
- C07C215/80—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton of the same non-condensed six-membered aromatic ring containing at least two amino groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/42—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/43—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
- Neurology (AREA)
- Otolaryngology (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9913083.3A GB9913083D0 (en) | 1999-06-04 | 1999-06-04 | Organic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
BE2010C011I2 true BE2010C011I2 (el) | 2019-05-21 |
Family
ID=10854788
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BE2010C011C BE2010C011I2 (el) | 1999-06-04 | 2010-02-24 |
Country Status (38)
Country | Link |
---|---|
US (9) | US6878721B1 (el) |
EP (2) | EP2332915B1 (el) |
JP (1) | JP3785365B2 (el) |
KR (1) | KR100718615B1 (el) |
CN (1) | CN1156451C (el) |
AR (1) | AR035548A1 (el) |
AT (1) | ATE440083T1 (el) |
AU (1) | AU765919B2 (el) |
BE (1) | BE2010C011I2 (el) |
BR (1) | BRPI0011324B8 (el) |
CA (1) | CA2375810C (el) |
CO (1) | CO5170518A1 (el) |
CY (3) | CY1109604T1 (el) |
CZ (1) | CZ302403B6 (el) |
DE (2) | DE122010000009I2 (el) |
DK (2) | DK1183240T3 (el) |
ES (2) | ES2402535T3 (el) |
FR (1) | FR10C0006I2 (el) |
GB (1) | GB9913083D0 (el) |
HK (2) | HK1045837B (el) |
HU (1) | HU227034B1 (el) |
IL (2) | IL146578A0 (el) |
LU (1) | LU91651I2 (el) |
MX (1) | MXPA01012474A (el) |
MY (1) | MY126951A (el) |
NL (1) | NL300437I1 (el) |
NO (2) | NO322944B1 (el) |
NZ (1) | NZ515669A (el) |
PE (1) | PE20010219A1 (el) |
PL (1) | PL198847B1 (el) |
PT (2) | PT1183240E (el) |
RU (1) | RU2244709C2 (el) |
SI (1) | SI1183240T1 (el) |
SK (1) | SK287260B6 (el) |
TR (1) | TR200103497T2 (el) |
TW (1) | TWI253447B (el) |
WO (1) | WO2000075114A1 (el) |
ZA (1) | ZA200109931B (el) |
Families Citing this family (172)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR028948A1 (es) | 2000-06-20 | 2003-05-28 | Astrazeneca Ab | Compuestos novedosos |
GB0029562D0 (en) * | 2000-12-04 | 2001-01-17 | Novartis Ag | Organic compounds |
TWI243164B (en) | 2001-02-13 | 2005-11-11 | Aventis Pharma Gmbh | Acylated indanyl amines and their use as pharmaceuticals |
GB0121214D0 (en) * | 2001-08-31 | 2001-10-24 | Btg Int Ltd | Synthetic method |
US6653323B2 (en) | 2001-11-13 | 2003-11-25 | Theravance, Inc. | Aryl aniline β2 adrenergic receptor agonists |
TWI249515B (en) | 2001-11-13 | 2006-02-21 | Theravance Inc | Aryl aniline beta2 adrenergic receptor agonists |
EP2311818B1 (en) | 2002-02-28 | 2013-01-16 | Novartis AG | Combination of a 5-phenylthiazole compound as PI3 kinase inhibitor with an antiinflammatory, bronchodilatory or antihistamine drug |
US6933410B2 (en) | 2002-03-08 | 2005-08-23 | Novartis Ag | Process for preparing 5,6-diethyl-2,3-dihydro-1H-inden-2-amine |
US7250426B2 (en) * | 2002-11-29 | 2007-07-31 | Boehringer Ingelheim Pharma Gmbh & Co Kg | Tiotropium-containing pharmaceutical combination for inhalation |
DE10256080A1 (de) * | 2002-11-29 | 2004-06-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Tiotropiumhaltige Arzneimittelkombination für die Inhalation |
PE20040950A1 (es) | 2003-02-14 | 2005-01-01 | Theravance Inc | DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS |
TWI324150B (en) | 2003-02-28 | 2010-05-01 | Novartis Ag | Process for preparing 5-[(r)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-(1h)-quinolin-2-one salt |
PE20050211A1 (es) * | 2003-04-02 | 2005-04-27 | Novartis Ag | Procedimiento para preparar oxi-(1h)-quinolin-2-onas 5-(alfa-haloacetil)-8-sustituidas |
GB0307856D0 (en) * | 2003-04-04 | 2003-05-14 | Novartis Ag | Organic compounds |
DE602004019198D1 (de) * | 2003-04-04 | 2009-03-12 | Novartis Ag | Chinolin-2-on-derivate zur behandlung von erkankungen der atemwege |
AR044519A1 (es) | 2003-05-02 | 2005-09-14 | Novartis Ag | Derivados de piridin-tiazol amina y de pirimidin-tiazol amina |
TW200526547A (en) | 2003-09-22 | 2005-08-16 | Theravance Inc | Amino-substituted ethylamino β2 adrenergic receptor agonists |
TW200531692A (en) | 2004-01-12 | 2005-10-01 | Theravance Inc | Aryl aniline derivatives as β2 adrenergic receptor agonists |
GB0401334D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
EP1574501A1 (en) * | 2004-03-11 | 2005-09-14 | Pfizer Limited | Quinolinone derivatives, pharmaceutical compositions containing them and their use |
WO2005092861A1 (en) * | 2004-03-11 | 2005-10-06 | Pfizer Limited | Quinolinone derivatives pharmaceutical compositions containing them and their use |
EP1729729B1 (en) | 2004-03-23 | 2014-04-23 | Novartis AG | Pharmaceutical compositions |
GB0410712D0 (en) | 2004-05-13 | 2004-06-16 | Novartis Ag | Organic compounds |
GB0411056D0 (en) * | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
ES2257152B1 (es) * | 2004-05-31 | 2007-07-01 | Laboratorios Almirall S.A. | Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos. |
GB0413960D0 (en) * | 2004-06-22 | 2004-07-28 | Novartis Ag | Organic compounds |
WO2006031556A2 (en) * | 2004-09-10 | 2006-03-23 | Theravance. Inc. | Amidine substituted aryl aniline compounds |
GT200500281A (es) | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
GB0424284D0 (en) | 2004-11-02 | 2004-12-01 | Novartis Ag | Organic compounds |
GB0426164D0 (en) | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
GB0507577D0 (en) | 2005-04-14 | 2005-05-18 | Novartis Ag | Organic compounds |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
GB0511065D0 (en) * | 2005-05-31 | 2005-07-06 | Novartis Ag | Organic compounds |
GB0511066D0 (en) * | 2005-05-31 | 2005-07-06 | Novartis Ag | Organic compounds |
TW200738634A (en) | 2005-08-02 | 2007-10-16 | Astrazeneca Ab | New salt |
US7994211B2 (en) | 2005-08-08 | 2011-08-09 | Argenta Discovery Limited | Bicyclo[2.2.1]hept-7-ylamine derivatives and their uses |
GB0516313D0 (en) | 2005-08-08 | 2005-09-14 | Argenta Discovery Ltd | Azole derivatives and their uses |
TW200738658A (en) | 2005-08-09 | 2007-10-16 | Astrazeneca Ab | Novel compounds |
AU2006282122A1 (en) * | 2005-08-26 | 2007-03-01 | Astrazeneca Ab | A combination of compounds, which can be used in the treatment of respiratory diseases, especially chronic obstructive pulmonary disease (COPD) and asthma |
BRPI0617485B8 (pt) | 2005-10-21 | 2021-05-25 | Novartis Ag | anticorpo anti-il-13 humano isolado, composição farmacêutica e uso do referido anticorpo |
TWI392493B (zh) * | 2005-10-26 | 2013-04-11 | Novartis Ag | 格隆溴銨(GLYCOPYRROLATE)及β2腎上腺素受體激動劑之組合 |
GB0525671D0 (en) | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
GB0526244D0 (en) | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
GB0602778D0 (en) | 2006-02-10 | 2006-03-22 | Glaxo Group Ltd | Novel compound |
TW200745067A (en) | 2006-03-14 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
SI2013211T1 (sl) | 2006-04-21 | 2012-07-31 | Novartis Ag | Purinski derivati za uporabo kot agonisti receptorja adenozina A A |
EP2044025B1 (en) * | 2006-06-30 | 2012-10-03 | Novartis AG | Quinolinone derivatives and their pharmaceutical compositions |
EP1878722A1 (en) * | 2006-07-13 | 2008-01-16 | Novartis AG | Quinolinone derivatives and their pharmaceutical compositions |
EP1914227A1 (en) * | 2006-08-31 | 2008-04-23 | Novartis AG | Polymorphic crystal form of a indan-2-ylamino-hydroxyethyl-quinolinone maleate derivative as beta-adrenoceptor agonist |
MX2009003185A (es) | 2006-09-29 | 2009-04-03 | Novartis Ag | Pirazolopirimidinas como inhibidores de lipido cinasa pi3k. |
CA2667962A1 (en) | 2006-10-30 | 2008-05-08 | Novartis Ag | Heterocyclic compounds as antiinflammatory agents |
TW200833670A (en) | 2006-12-20 | 2008-08-16 | Astrazeneca Ab | Novel compounds 569 |
WO2008085608A1 (en) | 2007-01-10 | 2008-07-17 | Irm Llc | Compounds and compositions as channel activating protease inhibitors |
GB0702458D0 (en) | 2007-02-08 | 2007-03-21 | Astrazeneca Ab | Salts 668 |
EP2117541A1 (en) | 2007-02-09 | 2009-11-18 | Irm Llc | Compounds and compositions as channel activating protease inhibitors |
PE20090733A1 (es) | 2007-05-07 | 2009-07-17 | Novartis Ag | Derivados de pirazina como bloqueadores de los canales de sodio epitelial |
BRPI0820669A2 (pt) | 2007-12-10 | 2020-08-04 | Novartis Ag | compostos orgânicos |
PT2231642E (pt) | 2008-01-11 | 2014-03-12 | Novartis Ag | Pirimidinas como inibidores de quinase |
US8268834B2 (en) | 2008-03-19 | 2012-09-18 | Novartis Ag | Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme |
ES2535736T3 (es) | 2008-06-10 | 2015-05-14 | Novartis Ag | Derivados de pirazina como bloqueadores de los canales de sodio epitelial |
EP2303873A4 (en) | 2008-06-18 | 2012-01-04 | Astrazeneca Ab | BENZOXAZINE DERIVATIVES AS A BETA2 ADRENORE RECEPTOR AGONIST FOR THE TREATMENT OF RESPIRATORY DISEASES |
US8236786B2 (en) | 2008-08-07 | 2012-08-07 | Pulmagen Therapeutics (Inflammation) Limited | Respiratory disease treatment |
MX2011007036A (es) | 2008-12-30 | 2011-07-20 | Pulmagen Therapeutics Inflammation Ltd | Compuestos de sulfonamida para el tratamiento de trastornos respiratorios. |
PL2391366T3 (pl) | 2009-01-29 | 2013-04-30 | Novartis Ag | Podstawione benzimidazole do leczenia gwiaździaków |
UY32442A (es) * | 2009-02-13 | 2010-09-30 | Sanofi Aventis | Nuevos indanos sustituidos, procesos para su preparacion y uso de los mismos como un medicamento |
WO2010150014A1 (en) | 2009-06-24 | 2010-12-29 | Pulmagen Therapeutics (Inflammation) Limited | 5r- 5 -deuterated glitazones for respiratory disease treatment |
US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
KR20120089643A (ko) | 2009-08-12 | 2012-08-13 | 노파르티스 아게 | 헤테로시클릭 히드라존 화합물, 및 암 및 염증을 치료하기 위한 그의 용도 |
WO2011022439A1 (en) | 2009-08-17 | 2011-02-24 | Intellikine, Inc. | Heterocyclic compounds and uses thereof |
JP5775871B2 (ja) | 2009-08-20 | 2015-09-09 | ノバルティス アーゲー | ヘテロ環式オキシム化合物 |
AU2010310449A1 (en) | 2009-10-22 | 2012-05-03 | Vertex Pharmaceuticals Incorporated | Compositions for treatment of cystic fibrosis and other chronic diseases |
GB0918924D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Azaindole derivatives |
GB0918922D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Aminopyridine derivatives |
GB0918923D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Aminothiazole derivatives |
WO2011056929A1 (en) * | 2009-11-04 | 2011-05-12 | Massachusetts Institute Of Technology | Continuous flow synthesis of amino alcohols using microreactors |
WO2011098746A1 (en) | 2010-02-09 | 2011-08-18 | Pulmagen Therapeutics (Inflammation) Limited | Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone |
GB201002224D0 (en) | 2010-02-10 | 2010-03-31 | Argenta Therapeutics Ltd | Respiratory disease treatment |
GB201002243D0 (en) | 2010-02-10 | 2010-03-31 | Argenta Therapeutics Ltd | Respiratory disease treatment |
KR20130004296A (ko) * | 2010-02-18 | 2013-01-09 | 아스트라제네카 아베 | 시클로프로필 아미드 유도체의 제조 방법 및 그와 관련된 중간체 |
US8680303B2 (en) | 2010-03-01 | 2014-03-25 | Massachusetts Institute Of Technology | Epoxidation catalysts |
US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
HUE031710T2 (en) | 2010-07-14 | 2017-07-28 | Novartis Ag | IP receptor agonist heterocyclic compounds |
WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
US8637516B2 (en) | 2010-09-09 | 2014-01-28 | Irm Llc | Compounds and compositions as TRK inhibitors |
US8372845B2 (en) | 2010-09-17 | 2013-02-12 | Novartis Ag | Pyrazine derivatives as enac blockers |
US10179139B2 (en) | 2010-10-12 | 2019-01-15 | Cipla Limited | Pharmaceutical composition |
JOP20120023B1 (ar) | 2011-02-04 | 2022-03-14 | Novartis Ag | صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية |
EP2673277A1 (en) | 2011-02-10 | 2013-12-18 | Novartis AG | [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase |
US9127000B2 (en) | 2011-02-23 | 2015-09-08 | Intellikine, LLC. | Heterocyclic compounds and uses thereof |
US9102671B2 (en) | 2011-02-25 | 2015-08-11 | Novartis Ag | Compounds and compositions as TRK inhibitors |
US8883819B2 (en) | 2011-09-01 | 2014-11-11 | Irm Llc | Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension |
CA2848809A1 (en) | 2011-09-15 | 2013-03-21 | Novartis Ag | 6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyradines as c-met tyrosine kinase |
WO2013038378A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
WO2013038386A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Heterocyclic compounds for the treatment of cystic fibrosis |
EP2755652B1 (en) | 2011-09-16 | 2021-06-02 | Novartis AG | N-substituted heterocyclyl carboxamides |
WO2013038381A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine/pyrazine amide derivatives |
WO2013038373A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
WO2013078440A2 (en) | 2011-11-23 | 2013-05-30 | Intellikine, Llc | Enhanced treatment regimens using mtor inhibitors |
US9115129B2 (en) | 2012-01-13 | 2015-08-25 | Novartis Ag | Substituted pyrido[2,3-B]pyrazines as IP receptor agonists |
WO2013105057A1 (en) | 2012-01-13 | 2013-07-18 | Novartis Ag | Fused pyrroles as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders |
WO2013105058A1 (en) | 2012-01-13 | 2013-07-18 | Novartis Ag | 7,8- dihydropyrido [3, 4 - b] pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders |
US20150005311A1 (en) | 2012-01-13 | 2015-01-01 | Novartis Ag | IP receptor agonist heterocyclic compounds |
WO2013105066A1 (en) | 2012-01-13 | 2013-07-18 | Novartis Ag | Salts of an ip receptor agonist |
WO2013105061A1 (en) | 2012-01-13 | 2013-07-18 | Novartis Ag | Fused dihydropyrido [2,3 -b] pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders |
WO2013132514A2 (en) * | 2012-03-09 | 2013-09-12 | Rao Davuluri Ramamohan | A novel process for the preparation of (r)-5-[2-[(5, 6-diethyl-2, 3-dihydro-1h-inden-2-yl) amino]-1-hydroxyethyl]-8-hydroxy quinolin-2(1h)-one |
US8809340B2 (en) | 2012-03-19 | 2014-08-19 | Novartis Ag | Crystalline form |
MX371119B (es) | 2012-04-03 | 2020-01-17 | Novartis Ag | Productos de combinacion con los inhibidores de cinasa de tirosina y su uso. |
CN104379566B (zh) * | 2012-07-11 | 2016-08-24 | 上海威智医药科技有限公司 | 茚达特罗中间体及茚达特罗的合成方法 |
WO2014008639A1 (zh) * | 2012-07-11 | 2014-01-16 | 上海威智医药科技有限公司 | 制备茚达特罗的方法 |
CN103539677B (zh) * | 2012-07-16 | 2015-04-22 | 武汉万知生物医药有限公司 | 一种5,6-二乙基-2,3-二氢-1h-茚-2-胺盐酸盐的制备方法 |
WO2014044288A1 (en) | 2012-09-21 | 2014-03-27 | Crystal Pharma Sa | Methods for the preparation of indacaterol and pharmaceutically acceptable salts thereof |
EP2897937B1 (en) | 2012-09-21 | 2017-12-06 | Crystal Pharma S.A.U | Process for the preparation of indacaterol and intermediates thereof |
JP6363616B2 (ja) | 2012-12-19 | 2018-07-25 | ノバルティス アーゲー | オートタキシン阻害剤 |
WO2014108449A1 (en) | 2013-01-08 | 2014-07-17 | Atrogi Ab | A screening method, a kit, a method of treatment and a compound for use in a method of treatment |
EP2956455B1 (en) | 2013-02-13 | 2017-05-17 | Novartis AG | Ip receptor agonist heterocyclic compounds |
US9073921B2 (en) | 2013-03-01 | 2015-07-07 | Novartis Ag | Salt forms of bicyclic heterocyclic derivatives |
MX2015012529A (es) | 2013-03-14 | 2016-07-05 | Novartis Ag | Deamorfizacion de formulaciones secadas por pulverizacion a traves de pulverizacion de la mezcla. |
US9452139B2 (en) | 2013-03-14 | 2016-09-27 | Novartis Ag | Respirable agglomerates of porous carrier particles and micronized drug |
CZ306252B6 (cs) * | 2013-03-15 | 2016-10-26 | Zentiva, K.S. | Způsob přípravy 5-[(R)-2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-(1H)-chinolin-2-onu (indacaterolu) |
CA2906542A1 (en) | 2013-03-15 | 2014-09-25 | Intellikine, Llc | Combination of kinase inhibitors and uses thereof |
WO2014154841A1 (en) * | 2013-03-27 | 2014-10-02 | Laboratorios Lesvi, S.L. | Process for the manufacture of (r)-5-[2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-(1h)-quinolin-2-one |
TN2016000022A1 (en) | 2013-07-18 | 2017-07-05 | Novartis Ag | Autotaxin inhibitors comprising a heteroaromatic ring-benzyl-amide-cycle core |
EP3022201A1 (en) | 2013-07-18 | 2016-05-25 | Novartis AG | Autotaxin inhibitors |
TW201605450A (zh) | 2013-12-03 | 2016-02-16 | 諾華公司 | Mdm2抑制劑與BRAF抑制劑之組合及其用途 |
CN104744360B (zh) * | 2013-12-26 | 2017-02-22 | 成都伊诺达博医药科技有限公司 | 一种合成茚达特罗的新方法 |
PT3092217T (pt) | 2014-01-09 | 2020-09-04 | Ramamohan Rao Davuluri | Processo inovador para preparação de indacaterol ou dos seus sais farmaceuticamente aceitáveis |
CN103830195A (zh) * | 2014-03-11 | 2014-06-04 | 熊妲妮 | 一种茚达特罗片及其制备方法 |
CN103830193A (zh) * | 2014-03-11 | 2014-06-04 | 熊妲妮 | 茚达特罗片制剂及其制备方法 |
KR20160137543A (ko) | 2014-03-27 | 2016-11-30 | 노파르티스 아게 | 활성 약제 성분의 흡입을 위한 분무-건조되는 수-중-유-중-고체 분산액 |
US20170037030A1 (en) | 2014-04-24 | 2017-02-09 | Novartis Ag | Autotaxin inhibitors |
WO2015162459A1 (en) | 2014-04-24 | 2015-10-29 | Novartis Ag | Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors |
KR20160141856A (ko) | 2014-04-24 | 2016-12-09 | 노파르티스 아게 | 포스파티딜이노시톨 3-키나제 억제제로서의 피라진 유도체 |
US10112926B2 (en) | 2014-04-24 | 2018-10-30 | Novartis Ag | Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors |
WO2016011658A1 (en) | 2014-07-25 | 2016-01-28 | Novartis Ag | Combination therapy |
EP3174869B1 (en) | 2014-07-31 | 2020-08-19 | Novartis AG | Combination therapy of a met inhibitor and an egfr inhibitor |
DE102014217205A1 (de) | 2014-08-28 | 2016-03-03 | Henkel Ag & Co. Kgaa | Verwendung einer Kombination von Rheolate FX 1100 und Luviskol VA 64 W |
DE102014217201A1 (de) | 2014-08-28 | 2016-03-03 | Henkel Ag & Co. Kgaa | Verwendung einer Kombination von Rheolate FX 1100 und Luviskol K90 |
CN107111687A (zh) | 2015-01-20 | 2017-08-29 | 诺华股份有限公司 | 使用连接的物理设备以及其间的数据传输进行应用解锁 |
ES2758677T3 (es) * | 2015-01-20 | 2020-05-06 | Olon Spa | Procedimiento para la preparación de derivados de indanamina y nuevos compuestos intermedios de síntesis |
WO2016161956A1 (zh) * | 2015-04-09 | 2016-10-13 | 正大天晴药业集团股份有限公司 | 茚达特罗或其盐的制备方法 |
PT3111978T (pt) | 2015-07-03 | 2021-12-06 | Novartis Ag | Inalador adaptado para ler informação armazenada num meio de armazenamento de dados de um recipiente |
ITUB20153978A1 (it) * | 2015-09-28 | 2017-03-28 | Laboratorio Chimico Int S P A | Procedimento per la preparazione di derivati di indanammina e di nuovi intermedi di sintesi. |
CN105884626B (zh) * | 2016-05-04 | 2017-10-20 | 龙曦宁(上海)医药科技有限公司 | 一种2‑氨基茚满衍生物的合成方法及其产品 |
CN108101841B (zh) * | 2016-11-24 | 2021-04-06 | 江苏恒瑞医药股份有限公司 | 一种制备茚达特罗或其盐的方法 |
GB201714740D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
GB201714745D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
GB201714734D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
GB201714736D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
WO2019135101A1 (en) | 2018-01-02 | 2019-07-11 | Deva Holding Anonim Sirketi | A process for preparation of 5-(2-(substituted-amino)-1-hydroxyethyl)-8-(substituted-oxy) quinolin-2(1h)-one |
WO2019182721A1 (en) | 2018-03-19 | 2019-09-26 | Dow Silicones Corporation | Polyolefin-polydiorganosiloxane block copolymer and hydrosilylaton reaction method for the synthesis thereof |
US11193051B2 (en) | 2018-03-19 | 2021-12-07 | Dow Silicones Corporation | Hot melt adhesive composition containing a polyolefin-polydiorganosiloxane copolymer and methods for the preparation and use thereof |
EP3768793B1 (en) | 2018-03-19 | 2023-09-27 | Dow Silicones Corporation | Polyorganosiloxane hot melt adhesive compositions containing polyolefin - polydiorganoosiloxane copolymers and methods for the preparation and use thereof |
CN112334515B (zh) | 2018-07-17 | 2022-08-09 | 美国陶氏有机硅公司 | 聚硅氧烷树脂-聚烯烃共聚物及其制备和使用方法 |
WO2020047225A1 (en) | 2018-08-30 | 2020-03-05 | Theravance Biopharma R&D Ip, Llc | Methods for treating chronic obstructive pulmonary disease |
MX2021003819A (es) | 2018-10-05 | 2021-06-23 | Vertex Pharma | Moduladores de alfa-1 antitripsina. |
CN109369417B (zh) * | 2018-10-19 | 2021-07-06 | 诚达药业股份有限公司 | 一种2-氨基茚满衍生物的制备方法 |
US20200163955A1 (en) | 2018-11-22 | 2020-05-28 | Glenmark Specialty S.A. | Sterile compositions of indacaterol suitable for nebulization |
WO2020141472A1 (en) | 2019-01-03 | 2020-07-09 | Glenmark Specialty S.A. | Nebulization composition comprising tiotropium and indacaterol |
CN109896966B (zh) * | 2019-04-04 | 2021-10-22 | 上海工程技术大学 | 一种n,n-二丁基间氨基苯酚的制备方法 |
CN109896967B (zh) * | 2019-04-04 | 2021-10-22 | 上海工程技术大学 | 一种间二乙氨基苯酚的制备方法 |
UY38696A (es) | 2019-05-14 | 2020-11-30 | Vertex Pharma | Moduladores de alfa-1 antitripsina |
CN110229078A (zh) * | 2019-05-22 | 2019-09-13 | 博诺康源(北京)药业科技有限公司 | 一种茚达特罗起始原料开环杂质的制备 |
CN113891744A (zh) | 2019-06-10 | 2022-01-04 | 诺华股份有限公司 | 用于治疗cf、copd和支气管扩张的吡啶和吡嗪衍生物 |
MX2022002374A (es) | 2019-08-28 | 2022-03-29 | Novartis Ag | Derivados de 1,3-fenil heteroarilo sustituidos y su uso en el tratamiento de enfermedades. |
TW202140550A (zh) | 2020-01-29 | 2021-11-01 | 瑞士商諾華公司 | 使用抗tslp抗體治療炎性或阻塞性氣道疾病之方法 |
CN115697969A (zh) * | 2020-04-03 | 2023-02-03 | 弗特克斯药品有限公司 | 作为用于治疗α-1抗胰蛋白酶缺乏症(AATD)的α-1抗胰蛋白酶调节剂的7-或8-羟基-异喹啉和7-或8-羟基-喹啉衍生物 |
CR20230125A (es) | 2020-08-14 | 2023-05-11 | Novartis Ag | Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos |
WO2022073009A1 (en) | 2020-09-29 | 2022-04-07 | iPharma Labs, Inc. | Liquid formulations of indacaterol |
CN115677577A (zh) * | 2021-11-03 | 2023-02-03 | 中国药科大学 | 靶向srsf6蛋白的小分子化合物及其制备方法和用途 |
GB202205895D0 (en) | 2022-04-22 | 2022-06-08 | Atrogi Ab | New medical uses |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8707123D0 (en) | 1987-03-25 | 1987-04-29 | Pfizer Ltd | Antiarrhythmic agents |
ZA903906B (en) * | 1989-05-25 | 1992-02-26 | Takeda Chemical Industries Ltd | Benzocycloalkane derivatives and production thereof |
AU632809B2 (en) | 1989-05-25 | 1993-01-14 | Takeda Chemical Industries Ltd. | Benzocycloalkane benzopyran and benzothiopyran urea derivatives and production thereof |
GB9107827D0 (en) * | 1991-04-12 | 1991-05-29 | Fujisawa Pharmaceutical Co | New ethanolamine derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same |
JPH0518007A (ja) | 1991-07-05 | 1993-01-26 | Konoike Constr Ltd | 鉄骨梁との接合部を内蔵したpc柱 |
IL104567A (en) | 1992-02-03 | 1997-03-18 | Fujisawa Pharmaceutical Co | Ethanolamine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same |
WO1993018007A1 (en) * | 1992-03-13 | 1993-09-16 | Tokyo Tanabe Company Limited | Novel carbostyril derivative |
DE69317399T2 (de) | 1993-01-29 | 1998-07-02 | American Cyanamid Co | Aminocycloalkanobenzodioxole als beta-3 selektive adrenergische Wirkstoffe |
DK0712387T3 (da) | 1993-08-06 | 2000-05-29 | Upjohn Co | 2-Aminoindaner som selektive dopamin-D3-ligander |
FR2711407B1 (fr) * | 1993-10-19 | 1996-01-26 | Allevard Sa | Perfectionnements aux barres de torsion métalliques. |
US5578638A (en) | 1993-11-05 | 1996-11-26 | American Cyanamid Company | Treatment of glaucoma and ocular hypertension with β3 -adrenergic agonists |
GB9405019D0 (en) | 1994-03-15 | 1994-04-27 | Smithkline Beecham Plc | Novel compounds |
PT807101E (pt) | 1995-02-01 | 2001-12-28 | Upjohn Co | 2-aminoindanos comoligandos selectivos de dopamina d3 |
ZA967892B (en) | 1995-09-21 | 1998-03-18 | Lilly Co Eli | Selective β3 adrenergic agonists. |
TW375604B (en) * | 1996-02-19 | 1999-12-01 | Kissei Pharmaceutical | 3,4-di-substituting phenyl-ethanolamine-tetrahydronaphthyl carboxylic amide derivatives |
JP3708624B2 (ja) * | 1996-03-27 | 2005-10-19 | キッセイ薬品工業株式会社 | 3,4−ジ置換フェニルエタノールアミノテトラリンカルボン酸誘導体 |
JP3690071B2 (ja) | 1997-06-24 | 2005-08-31 | 井関農機株式会社 | ロータリ耕耘具の防護装置 |
AU8562098A (en) * | 1997-08-19 | 1999-03-08 | Kissei Pharmaceutical Co. Ltd. | Phenylethanolaminotetralin derivatives and bronchodilators |
DE69940484D1 (de) * | 1998-04-06 | 2009-04-09 | Astellas Pharma Inc | Verwendung von beta-3-adrenergen-Rezeptoren Agonisten in der Behandlung von Dysurie |
BR0112297A (pt) | 2000-06-27 | 2003-05-06 | S A L V A T Lab Sa | Compostos carbamatos derivados de arilalquilaminas |
-
1999
- 1999-06-04 GB GBGB9913083.3A patent/GB9913083D0/en not_active Ceased
-
2000
- 2000-05-10 TW TW089108928A patent/TWI253447B/zh active
- 2000-05-26 MY MYPI20002328A patent/MY126951A/en unknown
- 2000-05-29 CO CO00039577A patent/CO5170518A1/es active IP Right Grant
- 2000-06-01 AR ARP000102709A patent/AR035548A1/es active IP Right Grant
- 2000-06-02 BR BRPI0011324A patent/BRPI0011324B8/pt not_active IP Right Cessation
- 2000-06-02 AT AT00935163T patent/ATE440083T1/de active
- 2000-06-02 US US10/009,008 patent/US6878721B1/en active Active
- 2000-06-02 ES ES08171523T patent/ES2402535T3/es not_active Expired - Lifetime
- 2000-06-02 PT PT00935163T patent/PT1183240E/pt unknown
- 2000-06-02 ES ES00935163T patent/ES2331457T3/es not_active Expired - Lifetime
- 2000-06-02 DE DE201012000009 patent/DE122010000009I2/de active Active
- 2000-06-02 MX MXPA01012474A patent/MXPA01012474A/es active IP Right Grant
- 2000-06-02 PT PT81715237T patent/PT2332915E/pt unknown
- 2000-06-02 CA CA2375810A patent/CA2375810C/en not_active Expired - Lifetime
- 2000-06-02 EP EP08171523A patent/EP2332915B1/en not_active Expired - Lifetime
- 2000-06-02 DK DK00935163T patent/DK1183240T3/da active
- 2000-06-02 DE DE60042781T patent/DE60042781D1/de not_active Expired - Lifetime
- 2000-06-02 TR TR2001/03497T patent/TR200103497T2/xx unknown
- 2000-06-02 PL PL352100A patent/PL198847B1/pl unknown
- 2000-06-02 PE PE2000000548A patent/PE20010219A1/es not_active IP Right Cessation
- 2000-06-02 HU HU0201658A patent/HU227034B1/hu active Protection Beyond IP Right Term
- 2000-06-02 CZ CZ20014301A patent/CZ302403B6/cs unknown
- 2000-06-02 AU AU50745/00A patent/AU765919B2/en active Active
- 2000-06-02 SI SI200031045T patent/SI1183240T1/sl unknown
- 2000-06-02 SK SK1743-2001A patent/SK287260B6/sk not_active IP Right Cessation
- 2000-06-02 CN CNB008084874A patent/CN1156451C/zh not_active Expired - Lifetime
- 2000-06-02 IL IL14657800A patent/IL146578A0/xx active IP Right Grant
- 2000-06-02 RU RU2001135801/04A patent/RU2244709C2/ru active Protection Beyond IP Right Term
- 2000-06-02 NZ NZ515669A patent/NZ515669A/xx not_active IP Right Cessation
- 2000-06-02 WO PCT/EP2000/005058 patent/WO2000075114A1/en active IP Right Grant
- 2000-06-02 DK DK08171523.7T patent/DK2332915T3/da active
- 2000-06-02 JP JP2001501595A patent/JP3785365B2/ja not_active Expired - Lifetime
- 2000-06-02 EP EP00935163A patent/EP1183240B1/en not_active Expired - Lifetime
- 2000-06-02 KR KR1020017015568A patent/KR100718615B1/ko active Protection Beyond IP Right Term
-
2001
- 2001-11-19 IL IL146578A patent/IL146578A/en active Protection Beyond IP Right Term
- 2001-12-03 ZA ZA200109931A patent/ZA200109931B/en unknown
- 2001-12-03 NO NO20015912A patent/NO322944B1/no not_active IP Right Cessation
-
2002
- 2002-07-29 HK HK02105569.8A patent/HK1045837B/zh not_active IP Right Cessation
-
2005
- 2005-03-07 US US11/074,400 patent/US7622483B2/en not_active Expired - Lifetime
-
2009
- 2009-10-13 US US12/577,855 patent/US7820694B2/en not_active Expired - Fee Related
- 2009-11-11 CY CY20091101179T patent/CY1109604T1/el unknown
-
2010
- 2010-02-15 FR FR10C0006C patent/FR10C0006I2/fr active Active
- 2010-02-17 LU LU91651C patent/LU91651I2/fr unknown
- 2010-02-18 NL NL300437C patent/NL300437I1/nl unknown
- 2010-02-24 BE BE2010C011C patent/BE2010C011I2/fr unknown
- 2010-03-09 CY CY2010003C patent/CY2010003I2/el unknown
- 2010-07-02 NO NO2010014C patent/NO2010014I1/no unknown
- 2010-09-20 US US12/885,922 patent/US8067437B2/en not_active Expired - Fee Related
-
2011
- 2011-08-23 HK HK11108894.7A patent/HK1154584A1/xx not_active IP Right Cessation
- 2011-11-14 US US13/295,426 patent/US8283362B2/en not_active Expired - Lifetime
-
2012
- 2012-07-23 US US13/555,536 patent/US8436017B2/en not_active Expired - Fee Related
-
2013
- 2013-04-08 US US13/858,308 patent/US8658673B2/en not_active Expired - Fee Related
- 2013-05-24 CY CY20131100413T patent/CY1114120T1/el unknown
- 2013-11-11 US US14/076,478 patent/US8796307B2/en not_active Expired - Fee Related
-
2014
- 2014-08-04 US US14/450,692 patent/US9040559B2/en not_active Expired - Fee Related